SignalFDA/Bio

ROIVANT SCIENCES LTD. (ROIV) DISCUSSES FDA APPROVAL OF LISRAYA AS FIRST ORAL TARGETED THERAPY FOR DERMATOMYOSITIS - SLIDESHOW - SEEKINGALPHA

FDA approval of first oral targeted therapy for dermatomyositis marks a major regulatory milestone.

What changed

FDA approval of first oral targeted therapy for dermatomyositis marks a major regulatory milestone.

Why it matters

FDA approval of first oral targeted therapy for dermatomyositis marks a major regulatory milestone. — impact context not separately stored; see What changed.

Sources

seekingalpha